When we carried out this study, the recommendations for patients with MPE due to NSCLC were to test at least three biomarkers for targeted therapies, including EGFR, ALK, and ROS1, and with the possibility of treatment within clinical trials for tumors with other molecular alterations, with the aim of greater individualization of treatment and therapeutic efficacy and with considerable progress in identifying new mutations in patients with advanced NSCLC [5,6]. Here, EGFR is linked to non-small cell lung carcinoma.